Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial.
Fiche publication
Date publication
mai 2016
Journal
JAMA
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BOUCHE Olivier
Tous les auteurs :
Hammel P, Huguet F, van Laethem JL, Goldstein D, Glimelius B, Artru P, Borbath I, Bouché O, Shannon J, André T, Mineur L, Chibaudel B, Bonnetain F, Louvet C,
Lien Pubmed
Résumé
In locally advanced pancreatic cancer, the role of chemoradiotherapy is controversial and the efficacy of erlotinib is unknown.
Mots clés
Aged, Antineoplastic Agents, administration & dosage, Antineoplastic Combined Chemotherapy Protocols, therapeutic use, Chemoradiotherapy, Chemotherapy, Adjuvant, Deoxycytidine, administration & dosage, Disease Progression, Disease-Free Survival, Erlotinib Hydrochloride, administration & dosage, Female, Humans, Male, Middle Aged, Nausea, chemically induced, Pancreatic Neoplasms, drug therapy
Référence
JAMA. 2016 May;315(17):1844-53